Anecdotal evidence suggested that in patients treated with anti CTLA-4 mAb(ipilimumab) and subsequent palliative radiotherapy objective responses were detectedoutside the irradiation field, concurrent with increases in the titer of antibodiesagainst the shared tumor antigen NY-ESO1 [103]. The gene discussed is CTLA4; the disease is neoplasm.